The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 09, 2020

Filed:

Sep. 02, 2011
Applicants:

James J. Collins, Newton, MA (US);

Michael Koeris, Natick, MA (US);

Timothy Kuan-ta LU, Charlestown, MA (US);

Gregory Stephanopoulos, Winchester, MA (US);

Christopher Jongsoo Yoon, Seoul, KR;

Inventors:

James J. Collins, Newton, MA (US);

Michael Koeris, Natick, MA (US);

Timothy Kuan-Ta Lu, Charlestown, MA (US);

Tanguy My Chau, Palo Alto, CA (US);

Gregory Stephanopoulos, Winchester, MA (US);

Christopher Jongsoo Yoon, Seoul, KR;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 7/00 (2006.01); A61K 35/76 (2015.01); A61K 38/17 (2006.01); C07K 14/435 (2006.01); C07K 14/46 (2006.01); C12N 9/50 (2006.01);
U.S. Cl.
CPC ...
C12N 7/00 (2013.01); A61K 35/76 (2013.01); A61K 38/1767 (2013.01); C07K 14/43504 (2013.01); C07K 14/43563 (2013.01); C07K 14/463 (2013.01); C12N 9/503 (2013.01); C12N 2795/10221 (2013.01); C12N 2795/10231 (2013.01); C12N 2795/10232 (2013.01); C12N 2795/12032 (2013.01); C12N 2795/12043 (2013.01); C12N 2795/14132 (2013.01); C12N 2795/14143 (2013.01);
Abstract

The present invention is generally related to engineered bacteriophages expressing antimicrobial peptides or lytic enzymes or fragments thereof for targeting a broad spectrum of bacterial hosts, and for the long-term suppression of bacterial phage resistance for reducing bacterial infections. In some embodiments, bacteriophages express antimicrobial peptides or antimicrobial polypeptides (e.g. phage lytic enzymes) which are secreted from the host bacteria, or alternatively released upon lysis of the bacterial host cell. Aspects of the present invention also relate to the use of the engineered bacteriophages for the reduction of bacterial infections, both in a subject or for bioremediation purposes, in clinical settings and wound healing.


Find Patent Forward Citations

Loading…